RNN Rexahn Pharmaceuticals Inc.

0.62
-0.4  -39%
Previous Close 1.01
Open 0.61
Price To Book 3.62
Market Cap 23075520
Shares 37,521,170
Volume 11,499,951
Short Ratio 4.68
Av. Daily Volume 351,350

SEC filingsSee all SEC filings

  1. 8-K - Current report 19535776
  2. 424B5 - Prospectus [Rule 424(b)(5)] 19535773
  3. CT ORDER - Confidential treatment order 181237261
  4. 8-K - Current report 181214516
  5. 8-K - Current report 181190315

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Updated Phase 2 data presented at ASCO GI January 19, 2018 noted 38% ORR. Further data due later in 2019.
RX-3117 in combination with Abraxane
First-line pancreatic cancer
Phase 2a trial to be completed 1H 2019.
RX-3117
Advanced bladder cancer - 3rd line
Phase 2 enrolment stopped - noted December 2018. Will focus on combo trial with Keytruda to be initiated 2H 2019.
RX-5902
Triple negative breast cancer
Noted February 8, 2018 that development will be discontinued.
Archexin
Renal cell carcinoma (RCC) - cancer
Phase 2 trial planned.
Archexin
Hepatocellular carcinoma (HCC)

SEC Filings

  1. 8-K - Current report 19535776
  2. 424B5 - Prospectus [Rule 424(b)(5)] 19535773
  3. CT ORDER - Confidential treatment order 181237261
  4. 8-K - Current report 181214516
  5. 8-K - Current report 181190315
  6. 10-Q - Quarterly report [Sections 13 or 15(d)] 181157286
  7. SC 13G - Statement of acquisition of beneficial ownership by individuals 181144380
  8. SC 13G - Statement of acquisition of beneficial ownership by individuals 181140591
  9. 8-K - Current report 181129410
  10. 424B5 - Prospectus [Rule 424(b)(5)] 181128802